AzTrials
AzTrials

Athletic PerformanceNCT07748416

The Effects of Acute Nitrate and Caffeine Co-ingestion on Discipline-Specific Exercise Performance.

A study testing Caffeine and Dietary Nitrate (Beetroot Juice) in people with Athletic Performance and Dietary Supplement, run by Poznan University of Physical Education at 1 site in Poland.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

The purpose of this study is to investigate the acute, separate, and combined ergogenic effects of dietary nitrate (beetroot juice, BJ) and caffeine (CAF) supplementation on discipline-specific athletic performance. The project employs a double-blind, randomized, placebo-controlled, four-arm crossover design. Read more about this study

Who is it for?
Ages 16 to 45 yearsHealthy volunteers can take part
What is being tested?
Caffeine and Dietary Nitrate (Beetroot Juice)
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
112 participants
Where
1 sitePoland
Study dates
1 Oct 2026to 30 Jun 2029
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 16 to 45 years
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult

Who may be able to join

  • Cohort A (HIFT / CrossFit / Hyrox):
  • Aged 18-45 years.
  • Minimum of 2 years of systematic HIFT/CrossFit/Hyrox training experience.
  • Performing >4 training sessions per week.
  • Ability to perform the HYROX Physical Fitness Test (P'F'T) and has participated in at least one official HYROX event.
  • Possession of a valid medical certificate proving eligibility for competitive sports.
Show all 19Show fewer
  • Cohort B (Competitive Junior Swimmers):
  • Aged 16-19 years.
  • Active member of the Polish Junior National Swimming Team.
  • Minimum of 5 years of competitive swimming experience.
  • Current training volume of at least 8-10 pool training sessions per week.
  • Written informed consent obtained from both the participant and their legal guardian (for minors under 18).
  • C)Common Criteria for Both Cohorts:
  • No history of cardiovascular, respiratory, metabolic, or musculoskeletal disease contradicting high-intensity exercise or stimulant intake.
  • No known food allergies or adverse reactions to beetroot products or caffeine.
  • No current use of medications that alter nitrate/caffeine metabolism (e.g., proton pump inhibitors, antibiotics, phosphodiesterase inhibitors).
  • History of uneventful habituation to caffeine use during training/competition.
  • Willingness to abstain from dietary supplements, antibacterial mouthwashes, alcohol, and high-nitrate foods for 48 hours prior to each testing session.
  • Good general health and physical well-being.

Who cannot join

  • Occurrence of acute musculoskeletal injury or trauma during the study period.
  • Any medical or health contraindications (including severe menstrual disorders, planned pregnancy, or breastfeeding).
  • Failure or refusal to strictly adhere to the dietary, supplementation, and exercise testing protocols.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Natalia Główka, PhD contact

+48691756944

glowka@awf.poznan.pl

Poland1 site
  • Poznan University of Physical Education

    Poznan, Wielkopolska, 61-871

    Natalia Główka, 691756944, glowka@awf.poznan.pl

Other trials in Poland

About this study

Official title: The Acute Effects of Dietary Nitrate (Beetroot Juice), Caffeine, and Their Combination on Discipline-Specific Exercise Performance, Lactate Kinetics, and Physiological Responses in Trained Functional Fitness Athletes and Elite Junior Swimmers.

The purpose of this study is to investigate the acute, separate, and combined ergogenic effects of dietary nitrate (beetroot juice, BJ) and caffeine (CAF) supplementation on discipline-specific athletic performance. The project employs a double-blind, randomized, placebo-controlled, four-arm crossover design. It evaluates two highly distinct, heterogeneous populations of athletes: (A) adult high-intensity functional training (HIFT/CrossFit/Hyrox) competitors performing the standardized Hyrox Physical Fitness Test (P'F'T), and (B) elite junior competitive swimmers (National Team members) performing a progressive 8 × 100 m swimming test. The study will assess physical performance, lactate kinetics, subjective exertion, biochemical indices, psychological metrics, and gastrointestinal tolerance.

Read the detailed description

This project addresses a critical gap in sports nutrition literature regarding the potential synergistic, additive, or antagonistic interactions of caffeine (CAF) and dietary nitrate (beetroot juice, BJ) when co-administered. While CAF acts primarily as an adenosine receptor antagonist in the central nervous system to enhance motor unit recruitment and decrease perceived exertion, BJ acts as a physiological precursor to nitric oxide, improving peripheral muscle contractility, mitochondrial efficiency, and muscle perfusion.

To evaluate whether these effects are universal or discipline-specific, the trial employs a two-population cohort design:

  • Cohort A (HIFT/Hyrox): Investigates adult functional fitness athletes (aged 18-45) characterized by concurrent strength and endurance adaptations. They will perform the ecological Hyrox P'F'T.
  • Cohort B (Elite Junior Swimmers): Investigates elite junior national team swimmers (aged 16-19) during their centralized training camp. They will undergo the standardized progressive 8 × 100 m step-test.

Furthermore, this study will analyze whether individual hematological markers (iron status) and biochemical profiles correlate with the magnitude of the ergogenic response to establish prospective predictive biomarkers for customized sports nutrition.

Being tested
Caffeine, Dietary Nitrate (Beetroot Juice), Placebo (Maltodextrin Capsule), Placebo (Nitrate-Depleted Beetroot Juice)
Keywords
Caffeine, Sports nutrition, Swimming, High-Intensity Functional Training, Nitric oxide

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CaffeineDietary supplement

    Anhydrous caffeine administered orally in a hard gelatine capsule. To address the unique physiological profiles of the two cohorts, a highly specific, differentiated dosing protocol is implemented: Cohort A (adult functional fitness athletes) will receive a high-performance dose of 6 mg/kg body mass, while Cohort B (elite junior swimmers) will receive a safe, youth-adapted dose of 3 mg/kg body mass. In all experimental trials, the capsule is ingested exactly 60 minutes prior to the onset of the discipline-specific exercise test to match peak plasma caffeine concentration.

  • Dietary Nitrate (Beetroot Juice)Dietary supplement

    Concentrated beetroot juice (BJ) administered as a single, acute organic shot of 70 mL (Beet It Sport, James White Drinks Ltd., Ipswich, UK). Each active shot contains approximately 400 mg (equivalent to ~6.4 mmol) of inorganic nitrate. In contrast to chronic loading designs, this study evaluates purely acute effects; the shot is ingested exactly 3 hours (180 minutes) prior to the physical performance test to align with peak systemic concentration of plasma nitrite.

  • Placebo (Maltodextrin Capsule)Dietary supplement

    Placebo capsule containing inert maltodextrin powder. The capsule is identical in size, shape, weight, color (opaque), and texture to the active caffeine capsule to ensure robust blinding. It is administered at the exact same time point (60 minutes pre-exercise) according to the identical body-mass-adjusted dosing scheme (simulating either 3 mg/kg or 6 mg/kg).

  • Placebo (Nitrate-Depleted Beetroot Juice)Dietary supplement

    Nitrate-depleted beetroot juice (Beet It, James White Drinks Ltd., Ipswich, UK) administered as a 70 mL shot. This placebo is identical in taste, smell, appearance, packaging, and viscosity to the active concentrated shot, but has been selectively filtered to contain negligible nitrate levels (<0.4 mmol / ~25 mg of nitrates). It is ingested exactly 3 hours prior to the exercise test.

Study groups in NCT07748416
Study groupRoleWhat they receive
CAF + BJ (Active Co-ingestion)ExperimentalParticipants ingest a concentrated beetroot juice shot (~6.4 mmol / 400 mg nitrates) 3 hours before exercise, and a capsule of caffeine (Cohort A: 6 mg/kg body mass; Cohort B: 3 mg/kg body mass) 60 minutes before exercise.
Receives: Dietary Supplement: Caffeine; Dietary Supplement: Dietary Nitrate (Beetroot Juice)
CAF + PLBJ (Caffeine + Placebo BJ)Active comparatorParticipants ingest a nitrate-depleted beetroot juice shot (~0.04 mmol nitrates) 3 hours before exercise, and a capsule of caffeine (Cohort A: 6 mg/kg body mass; Cohort B: 3 mg/kg body mass) 60 minutes before exercise.
Receives: Dietary Supplement: Caffeine; Dietary Supplement: Placebo (Nitrate-Depleted Beetroot Juice)
PLCAF + BJ (Placebo CAF + Beetroot Juice)Active comparatorParticipants ingest a concentrated beetroot juice shot (~6.4 mmol / 400 mg nitrates) 3 hours before exercise, and a placebo capsule (maltodextrin) 60 minutes before exercise.
Receives: Dietary Supplement: Dietary Nitrate (Beetroot Juice); Dietary Supplement: Placebo (Maltodextrin Capsule)
PLCAF + PLBJ (Double Placebo Control)Placebo comparatorParticipants ingest a nitrate-depleted beetroot juice shot (~0.04 mmol nitrates) 3 hours before exercise, and a placebo capsule (maltodextrin) 60 minutes before exercise.
Receives: Dietary Supplement: Placebo (Maltodextrin Capsule); Dietary Supplement: Placebo (Nitrate-Depleted Beetroot Juice)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Exercise Performance Time (minutes and seconds, Cohort A - Hyrox P'F'T)

    Total time (in minutes and seconds) required to complete the standardized HYROX Physical Fitness Test (P'F'T) consisting of 6 specific functional exercises.

    Measured: At each experimental visit (Visits T1-T4), with visits conducted at 7-day intervals following the baseline/familiarization visit (T0).

  2. Swimming Performance (minutes and seconds, Cohort B - 8x100m Step-Test)

    Swimming performance will be assessed using the completion time (seconds and milliseconds) for each 100-m repetition of the standardized 8 × 100-m step test, including the maximal-effort repetition performed during the fifth stage.

    Measured: At each experimental visit (Visits T1-T4), with visits conducted at 7-day intervals following the baseline/familiarization visit (T0).

Secondary outcomes (31)
  1. Blood Lactate Kinetics (mmol/L)

    Blood lactate concentration, including peak concentration, accumulation kinetics, and clearance rate, will be assessed from fingertip capillary blood collected before supplementation (baseline), pre-exercise (3 hours after beetroot juice supplementation and 30 minutes after caffeine supplementation), and post-exercise (3 and 7 minutes after exercise) at each experimental visit.

    Measured: Before supplementation (baseline), pre-exercise (3 hours after beetroot juice supplementation and 30 minutes after caffeine supplementation), and 3 and 7 minutes after exercise at each experimental visit (Visits T1-T4; 7-day intervals).

  2. Heart Rate (HR, bpm)

    Real-time heart rate (beats per minute) will be continuously monitored throughout each exercise test using a telemetry-based heart rate monitoring system.

    Measured: Continuously monitored during exercise at each experimental visit (Visits T1-T4; 7-day intervals).

  3. Rating of Perceived Exertion (RPE, points)

    Subjective rating of perceived exertion will be assessed using the validated Borg Scale (6-20).

    Measured: Immediately after exercise at each experimental visit (Visits T1-T4; 7-day intervals).

  4. Blood Pressure (mmHg)

    Systolic and diastolic blood pressure will be measured using an automated oscillometric blood pressure monitor.

    Measured: Measured 2.5 hours after beetroot juice supplementation and 30 minutes after caffeine supplementation (pre-exercise) at each experimental visit (Visits T1-T4; 7-day intervals).

  5. Gastrointestinal Tolerance Profile (mVAS, points)

    Gastrointestinal symptoms will be assessed using the modified Visual Analog Scale (mVAS; 0-10, where 0 = no symptoms and 10 = extremely severe symptoms).

    Measured: Measured 30 minutes after supplementation and immediately after exercise at each experimental visit (Visits T1-T4; 7-day intervals).

  6. White blood cells count and differential (count/L)

    Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline) and 3 minutes after exercise at each experimental visit.

    Measured: Before supplementation (baseline) and 3 minutes after exercise at each experimental visit (Visits T1-T4; 7-day intervals).

  7. White blood cells count and differential (%)

    Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline) and 3 minutes after exercise at each experimental visit.

    Measured: Before supplementation (baseline) and 3 minutes after exercise at each experimental visit (Visits T1-T4; 7-day intervals).

  8. Hematological indices (red blood cells, RBC) (count/L)

    Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline) and 3 minutes after exercise at each experimental visit.

    Measured: Before supplementation (baseline) and 3 minutes after exercise at each experimental visit (Visits T1-T4; 7-day intervals).

  9. Hematological indices (hemoglobin concentration, HGB) (mmol/L)

    Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline) and 3 minutes after exercise at each experimental visit.

    Measured: Before supplementation (baseline) and 3 minutes after exercise at each experimental visit (Visits T1-T4; 7-day intervals).

  10. Hematological indices (hematocrit, HCT) (L/L)

    Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline) and 3 minutes after exercise at each experimental visit.

    Measured: Before supplementation (baseline) and 3 minutes after exercise at each experimental visit (Visits T1-T4; 7-day intervals).

  11. Hematological indices (mean corpuscular volume, MCV; mean platelet volume, MPV) (fL)

    Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline) and 3 minutes after exercise at each experimental visit.

    Measured: Before supplementation (baseline) and 3 minutes after exercise at each experimental visit (Visits T1-T4; 7-day intervals).

  12. Hematological indices (mean corpuscular hemoglobin mass, MCH) (fmol)

    Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline) and 3 minutes after exercise at each experimental visit.

    Measured: Before supplementation (baseline) and 3 minutes after exercise at each experimental visit (Visits T1-T4; 7-day intervals).

  13. Hematological indices (mean corpuscular hemoglobin concentration, MCHC) (mmol/L)

    Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline) and 3 minutes after exercise at each experimental visit.

    Measured: Before supplementation (baseline) and 3 minutes after exercise at each experimental visit (Visits T1-T4; 7-day intervals).

  14. Hematological indices (platelet count, PLT) (count/L)

    Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline) and 3 minutes after exercise at each experimental visit.

    Measured: Before supplementation (baseline) and 3 minutes after exercise at each experimental visit (Visits T1-T4; 7-day intervals).

  15. Hematological indices (platelet hematocrit, PCT) (cL/L)

    Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline) and 3 minutes after exercise at each experimental visit.

    Measured: Before supplementation (baseline) and 3 minutes after exercise at each experimental visit (Visits T1-T4; 7-day intervals).

  16. Hematological indices (platelet distribution width, PDW; platelet large cell ratio, PLCR; red blood cells distribution width - coefficient of variation, RDW-C) (%)

    Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline) and 3 minutes after exercise at each experimental visit.

    Measured: Before supplementation (baseline) and 3 minutes after exercise at each experimental visit (Visits T1-T4; 7-day intervals).

  17. Hematological indices (red blood cells distribution width - standard deviation, RDW-S) (fL)

    Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline) and 3 minutes after exercise at each experimental visit.

    Measured: Before supplementation (baseline) and 3 minutes after exercise at each experimental visit (Visits T1-T4; 7-day intervals).

  18. Nutritional status indices (concentration of urea) (mmol/L)

    Urea concentration will be assessed from fingertip capillary blood collected before supplementation (baseline).

    Measured: Before supplementation (baseline) at each experimental visit (Visits T1-T4; 7-day intervals).

  19. Creatinine Concentration (μmol/L)

    Creatinine concentration will be assessed from fingertip capillary blood collected before supplementation (baseline).

    Measured: Before supplementation (baseline) at each experimental visit (Visits T1-T4; 7-day intervals).

  20. Muscle Damage Markers (ALT, AST, CK, LDH) (U/L)

    Activities of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatine kinase (CK), and lactate dehydrogenase (LDH) will be assessed from fingertip capillary blood collected before supplementation (baseline).

    Measured: Before supplementation (baseline) at each experimental visit (Visits T1-T4; 7-day intervals).

  21. Body composition (fat-free mass, fat mass) (kg)

    Body composition will be assessed before supplementation (baseline) using bioelectrical impedance analysis.

    Measured: Before supplementation (baseline) at each experimental visit (Visits T1-T4; 7-day intervals).

  22. Body composition (fat-free mass, fat mass) (%)

    Body composition will be assessed before supplementation (baseline) using bioelectrical impedance analysis.

    Measured: Before supplementation (baseline) at each experimental visit (Visits T1-T4; 7-day intervals).

  23. Body composition (total body water) (L)

    Body composition will be assessed before supplementation (baseline) using bioelectrical impedance analysis.

    Measured: Before supplementation (baseline) at each experimental visit (Visits T1-T4; 7-day intervals).

  24. Body composition (total body water) (%)

    Body composition will be assessed before supplementation (baseline) using bioelectrical impedance analysis.

    Measured: Before supplementation (baseline) at each experimental visit (Visits T1-T4; 7-day intervals).

  25. Iron Status (Iron, Ferritin, UIBC, TIBC) (μg/dL)

    Serum iron concentration, ferritin concentration, unsaturated iron-binding capacity (UIBC), and total iron-binding capacity (TIBC) will be assessed from fingertip capillary blood collected before supplementation (baseline).

    Measured: Before supplementation (baseline) at each experimental visit (Visits T1-T4; 7-day intervals).

  26. Iron Status (Transferrin Concentration) (g/L)

    Serum transferrin concentration will be assessed from fingertip capillary blood collected before supplementation (baseline).

    Measured: Before supplementation (baseline) at each experimental visit (Visits T1-T4; 7-day intervals).

  27. Sleep Quality (Visual Analog Scale, VAS; points)

    Subjective sleep quality will be assessed using a Visual Analog Scale (VAS).

    Measured: Before supplementation (baseline), pre-exercise, and immediately after exercise at each experimental visit (Visits T1-T4; 7-day intervals).

  28. Mood (Brunel Mood Scale, BRUMS; points)

    Mood state will be assessed using the Brunel Mood Scale (BRUMS).

    Measured: Before supplementation (baseline), pre-exercise, and immediately after exercise at each experimental visit (Visits T1-T4; 7-day intervals).

  29. Competitive State Anxiety (Revised Competitive State Anxiety Inventory-2, CSAI-2R; points)

    Competitive state anxiety will be assessed using the Revised Competitive State Anxiety Inventory-2 (CSAI-2R).

    Measured: Before supplementation (baseline), pre-exercise, and immediately after exercise at each experimental visit (Visits T1-T4; 7-day intervals).

  30. Felt Arousal (Felt Arousal Scale, FAS; points)

    Perceived arousal will be assessed using the Felt Arousal Scale (FAS).

    Measured: Before supplementation (baseline), pre-exercise, and immediately after exercise at each experimental visit (Visits T1-T4; 7-day intervals).

  31. Feeling Scale (FS; points)

    Affective valence will be assessed using the Feeling Scale (FS).

    Measured: Before supplementation (baseline), pre-exercise, and immediately after exercise at each experimental visit (Visits T1-T4; 7-day intervals).

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Aug 2026
  2. Study start1 Oct 2026 (estimated)
  3. Primary completion30 Jun 2029 (estimated)
  4. Study completion30 Jun 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Crossover
Model description
This study employs a double-blind, randomized, placebo-controlled, four-arm, crossover design to evaluate the acute, separate, and combined effects of caffeine (CAF) and dietary nitrate (beetroot juice, BJ) on athletic performance. Following a baseline familiarization session (T0), participants will complete four main experimental testing visits (T1-T4). Every participant will undergo all four interventional conditions in a randomized, counterbalanced sequence. A minimum 7-day (168-hour) washout period will separate each testing session to ensure complete physical recovery, muscle regeneration, and complete elimination of the active substances from the systemic circulation. The four interventional combinations administered across the testing visits are: Active BJ + Active CAF (CAF+BJ); Active CAF + BJ (CAF+PLBJ); Active BJ + Placebo CAF (PLCAF+BJ); Placebo BJ + Placebo CAF (PLCAF+PLBJ).
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
112 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07748416
Sponsor's protocol ID
ZDS2026_NG_001
Status last verified
Jul 2026
First submitted
17 Jul 2026
Last updated
7 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: The study protocol will be published as an open-access article. Upon completion of the study, de-identified individual participant data (IPD) and relevant analytic code will be deposited in an open-access repository such as Zenodo or OSF, following the FAIR principles.

Questions about this trial

What is this clinical trial studying?

A study testing Caffeine and Dietary Nitrate (Beetroot Juice) in people with Athletic Performance and Dietary Supplement, run by Poznan University of Physical Education at 1 site in Poland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 19 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 7 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Poland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Natalia Główka, PhD (+48691756944, glowka@awf.poznan.pl), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Exercise Performance Time (minutes and seconds, Cohort A - Hyrox P'F'T) (time frame: At each experimental visit (Visits T1-T4), with visits conducted at 7-day intervals following the baseline/familiarization visit (T0).). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in